News

Eli Lilly's Mounjaro hits Rs 24 crore sales in 3 months as adoption grows for diabetes and obesity in India
Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...
Novo’s Ozempic linked to rare cases of serious eye disorder, EU regulator says
This is the first time a regulator has confirmed the side effect. Read more at straitstimes.com. Read more at straitstimes.com.
The Zimbabwean on MSN5h
Digital Health Solutions For Non-Communicable Disease Care in Zimbabwe
Sharing data in real time to make critical health care decisionsConnecting rural and remote communities to Zimbabwe’s primary ...
MarketBeat on MSN18h
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...
Bank of America Securities Remains a Buy on Eli Lilly & Co (LLY)
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly is said to have posted 60% rise in obesity drug sales in India last month
Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.
81,000 Vials, Rs 24 Crore In 3 Months: Weight Loss Drug Mounjaro Sales Triple As Patients Shift To Higher Dose
With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March ...